In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....